RG
EPRX

Redmile Group’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Redmile Group’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.07M Buy
+700,000
New +$5.63M 0.34% 30

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Redmile Group's EPRX Position: Q1 2026 in Review

Redmile Group opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q1 2026: 700,000 shares worth $5.07M. The stake represents 0.34% of the portfolio and ranks #30 among its holdings.

54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Redmile Group held 700,000 shares of Eupraxia Pharmaceuticals worth $5.07M as of Q1 2026.
  • Eupraxia Pharmaceuticals was a new Redmile Group position in Q1 2026.
  • Eupraxia Pharmaceuticals made up 0.34% of Redmile Group's portfolio in Q1 2026, its #30 holding.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.